Eli Lilly's drug Jaypirca (generic name: pirtobrutinib) has received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP), supporting its approval for the treatment of adult patients with chronic lymphocytic leukemia (CLL) who have received any number of prior treatments.

Eli Lilly's drug Jaypirca (generic name: pirtobrutinib) has received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP), supporting its approval for the treatment of adult patients with chronic lymphocytic leukemia (CLL) who have received any number of prior treatments.

老虎证券2026/06/26 11:41

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

This positive opinion marks a critical step in the EU regulatory approval process for the drug, bringing new hope for treatment to the CLL patient community. If ultimately approved, Jaypirca will offer an important new option for patients who have undergone multiple lines of therapy and have limited choices.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

You may also like

Crypto prices